CUDC-427

· Curis, Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for CUDC-427, covering 2016-12-01 to 2016-12-01. Get the full timeline:

Most recent: Clinical Trial Update: Phase I Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-427 When Given to Patients With Advanced and Refractory Solid Tumors or Lymphoma [Phase 1]

See pricing